Clinical Trial of Covid-19 Convalescent Plasma in Outpatients (C3PO)
2 institutional releases
Published in New England Journal of Medicine · View the paper (DOI)
A NIH study published in The New England Journal of Medicine found that administering convalescent plasma to outpatients with early symptoms of COVID-19 did not prevent disease progression. The trial, which enrolled over 500 participants, showed a significant reduction of less than 2% in disease progression.
Coverage from 2 institutions
- NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms NIH/National Heart, Lung and Blood Institute · Aug 18, 2021 · first to report
- Lundquist Institute investigators find that early administration of convalescent plasma does not prevent COVID-19 disease progression The Lundquist Institute · Aug 18, 2021